STOCK TITAN

Alcon Inc - ALC STOCK NEWS

Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.

Alcon Inc. Ordinary Shares (symbol: ALC) is a premier American-Swiss healthcare company headquartered in Geneva, Switzerland, and incorporated in Fribourg, Switzerland. Renowned globally for its eye care products, Alcon excels in vision care and surgical segments, making it a leader in the eye care industry. Having spun off from Novartis in April 2019, Alcon now independently operates to enhance the quality of life through innovative vision products.

Alcon’s vision care segment includes a wide range of products such as contact lenses, lens care solutions, and ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon boasts significant control over the U.S. contact lens market. Their surgical segment offers advanced solutions like intraocular lenses (IOLs), ophthalmic surgical equipment, and consumables used during surgeries. Notable products include the Centurion phacoemulsification device and the Clareon, PanOptix, and Vivity IOLs.

Recently, Alcon launched the Clareon Vivity, which is the world’s first non-diffractive extended depth of focus (EDOF) intraocular lens. This innovative IOL incorporates wavefront-shaping technology, offering superior visual outcomes for cataract patients seeking presbyopia correction. The Clareon platform enhances Alcon's portfolio, which already includes the highly successful PanOptix lenses.

Financially, Alcon has shown robust growth. For Q4 2023, Alcon's sales reached $2.3 billion, marking an 8% increase from the previous year. Diluted EPS was $0.86, reflecting a 78% increase, and core diluted EPS was $0.70, up 67%. Alcon also reported a strong cash flow, with $937 million generated from operating activities in the first nine months of 2023.

Alcon's dedication to innovation and quality in eye care is further evidenced by its extensive research and development initiatives. The company engages in partnerships with eye care professionals and offers educational resources through the Alcon Experience Academy. Through consistent advancements and a customer-centric approach, Alcon continues to lead in enhancing sight and improving lives globally.

Rhea-AI Summary
Alcon announces full U.S. commercial availability of cloud-based cataract planner, SMARTCataract, which offers seamless connectivity for surgical ophthalmic practices. The platform has demonstrated significant time savings during the cataract evaluation, planning process, operating room, and postoperative workflow. Alcon will showcase its digital offerings at the upcoming American Academy of Ophthalmology (AAO) 2023 annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
Rhea-AI Summary
Alcon (SIX/NYSE: ALC) announced the global launch of TOTAL30® Multifocal, the first and only monthly Water Gradient multifocal contact lens. The lenses provide excellent visual acuity at all distances, addressing the vision and comfort needs of the global multifocal market, a rapidly growing market valued over $1 billion globally and growing double digit annually. The lenses have begun to roll out in the United States and select international markets, offering Alcon's premium Water Gradient innovation at a more accessible price point of monthly lenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
-
Rhea-AI Summary
Alcon's Vivity Registry Study demonstrates excellent outcomes with AcrySof IQ Vivity and AcrySof IQ Vivity Toric
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Alcon presents scientific data and innovations at the 41st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). Alcon's intraocular lens and surgical equipment portfolio showcased, including the next generation in refractive surgery. Alcon expands Global Medical Affairs website to support eye care professionals in multiple countries. Alcon to host symposia and booth talks on various topics related to cataract surgery. Alcon sponsors ESCRS iNovation Day and near-live surgery sessions. Alcon emphasizes commitment to sustainability. Please refer to relevant products DFU or Operator’s manuals for complete list of indications, contraindications, and warnings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
-
Rhea-AI Summary
Alcon, the global leader in eye care, reported sales of $2.4 billion in Q2 2023, a 9% increase compared to the previous year. Diluted EPS was $0.34, up 13%. The company raised its full-year 2023 sales and core diluted EPS guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none

FAQ

What is the current stock price of Alcon (ALC)?

The current stock price of Alcon (ALC) is $90.31 as of February 21, 2025.

What is the market cap of Alcon (ALC)?

The market cap of Alcon (ALC) is approximately 44.3B.

What does Alcon Inc. specialize in?

Alcon Inc. specializes in eye care products, including contact lenses, lens care solutions, ocular health products, intraocular lenses (IOLs), and ophthalmic surgical equipment.

When did Alcon become an independent company?

Alcon became an independent public company in April 2019, following its spin-off from Novartis.

What are Alcon’s major product brands in the vision care segment?

Major product brands in Alcon’s vision care segment include Dailies, Total1, and Air Optix.

What significant recent product has Alcon launched?

Alcon recently launched the Clareon Vivity, the first non-diffractive extended depth of focus (EDOF) intraocular lens, incorporating wavefront-shaping technology.

How did Alcon perform financially in Q4 2023?

In Q4 2023, Alcon reported sales of $2.3 billion, an 8% increase from the previous year, with a diluted EPS of $0.86 and a core diluted EPS of $0.70.

What educational resources does Alcon offer?

Alcon offers educational resources through the Alcon Experience Academy, providing training and education for eye care professionals and supporting staff.

Where is Alcon Inc. headquartered?

Alcon Inc. is headquartered in Geneva, Switzerland and incorporated in Fribourg, Switzerland.

What segments does Alcon operate in?

Alcon operates in two main segments: vision care and surgical.

How has Alcon shown its commitment to innovation?

Alcon shows its commitment to innovation through continuous research and development, launching cutting-edge products like Clareon Vivity IOL, and partnerships with eye care professionals.

Who are the primary beneficiaries of Alcon's products?

The primary beneficiaries of Alcon's products are individuals with eye conditions such as cataracts, glaucoma, retinal diseases, and refractive errors, along with eye care professionals.
Alcon Inc

NYSE:ALC

ALC Rankings

ALC Stock Data

44.30B
493.54M
0.19%
65.88%
0.66%
Medical Instruments & Supplies
Healthcare
Link
Switzerland
Geneva